IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) — As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OCTQB: IGXT; TSX:IGX), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, was granted protection pursuant to an initial order (as amended, the “Initial Order”) issued under the Companies’ Creditors Arrangement Act (“CCAA”) by the Québec Superior Court (Commercial Division) (the “Court”). The Initial Order appointed Ernst & Young Inc. as monitor (the “Monitor”) and authorized interim debtor-in-possession financing (DIP) financing provided by atai Life Sciences AG in order to allow the Company to continue its operations during the restructuring process and implement the necessary restructuring measures.
Related news for (IGXT)
- IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
- IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
- IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
- IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives